Core Insights - Structure Therapeutics is advancing its oral small molecule therapeutics for metabolic diseases, particularly obesity, with significant clinical milestones expected by the end of 2025 [1][2][5] Clinical Development - The Phase 2b ACCESS and ACCESS II studies for aleniglipron (GSBR-1290), an oral small molecule GLP-1 receptor agonist, are fully enrolled and on track for topline data readout by year-end 2025 [5] - ACCESS study enrolled approximately 220 adults with obesity or overweight with weight-related comorbidities, evaluating doses up to 120 mg of aleniglipron [5] - ACCESS II study enrolled approximately 80 adults, evaluating higher doses of aleniglipron (180 mg and 240 mg) [5] - The Phase 1 study for ACCG-2671, an oral small molecule amylin receptor agonist, is anticipated to initiate by year-end 2025 [1][2][5] Financial Position - As of March 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling $836.9 million, expected to fund operations through at least 2027 [7] - Research and Development (R&D) expenses for Q1 2025 were $42.9 million, up from $20.7 million in Q1 2024, primarily due to increased clinical trial costs and personnel expenses [8] - General and Administrative (G&A) expenses for Q1 2025 were $13.4 million, compared to $11.3 million in Q1 2024, driven by personnel-related expenses [9] - The net loss for Q1 2025 was $46.8 million, compared to a net loss of $26.0 million in Q1 2024 [10] Pipeline and Future Directions - Structure Therapeutics is exploring additional indications for GLP-1 receptor agonists beyond obesity, including Parkinson's disease, with preclinical data to be presented at the ADA 85 Scientific Sessions in June 2025 [5] - The company is also developing GIPR and GCGR selective agonists and antagonists, as well as evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential muscle-sparing weight loss [5][6]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) Cayman Islands 98-1480821 (State of ...

[Overview and Business Update](index=1&type=section&id=Overview%20and%20Business%20Update) Structure Therapeutics made significant advancements in its oral small molecule obesity portfolio in 2024, strengthening its financial position and preparing for key clinical data readouts in 2025 [Executive Summary](index=1&type=section&id=Executive%20Summary) Structure Therapeutics advanced its oral obesity portfolio in 2024, securing **$547 million** financing and preparing for key aleniglipron data in 2025 - Completed a **$547 million** financing in 2024, significantly strengthening the company's financial position[2](index=2&type=chunk) - The company is positioned as a leader with aleniglipron (GSBR-1290), the second most advanced oral GLP-1 small molecule, with 36-week data expected by year-end 2025[2](index=2&type=chunk) - The pipeline was expanded with the selection of an oral small molecule amylin receptor agonist, ACCG-2671, with Phase 1 development expected to begin by year-end 2025[1](index=1&type=chunk)[2](index=2&type=chunk) [Pipeline Development and Milestones](index=2&type=section&id=Pipeline%20Development%20and%20Milestones) The company advances its oral small molecule obesity pipeline, including aleniglipron, ACCG-2671, and other programs for combination therapies [Aleniglipron (GSBR-1290) – Oral Small Molecule Selective GLP-1R Agonist](index=2&type=section&id=Aleniglipron%20%28GSBR-1290%29%20%E2%80%93%20Oral%20Small%20Molecule%20Selective%20GLP-1R%20Agonist) Aleniglipron's ACCESS and ACCESS II studies completed enrollment, with 36-week data for doses up to 240 mg anticipated by year-end 2025 - The ACCESS and ACCESS II studies have completed enrollment on schedule, with a total of over **300 patients**[8](index=8&type=chunk) - The studies are designed to evaluate doses up to **120 mg** (ACCESS) and higher doses of **180 mg** and **240 mg** (ACCESS II)[8](index=8&type=chunk) - Topline 36-week data from both studies are expected by year-end 2025[1](index=1&type=chunk)[8](index=8&type=chunk) [ACCG-2671 – Oral Small Molecule Amylin Receptor Agonist](index=2&type=section&id=ACCG-2671%20%E2%80%93%20Oral%20Small%20Molecule%20Amylin%20Receptor%20Agonist) ACCG-2671, the first oral amylin receptor agonist, began IND-enabling activities in December 2024, with Phase 1 trials planned by year-end 2025 - Selected as the first development candidate in December 2024, with IND-enabling activities commenced[8](index=8&type=chunk) - The preclinical profile supports once-daily oral dosing in humans[8](index=8&type=chunk) - The company plans to initiate a Phase 1 clinical study by year-end 2025[1](index=1&type=chunk)[8](index=8&type=chunk) [Other Oral Small Molecule Obesity Pipeline Programs](index=2&type=section&id=Other%20Oral%20Small%20Molecule%20Obesity%20Pipeline%20Programs) The company develops other oral small molecule obesity programs, including GIPR and GCGR agonists for combination therapies, and a Phase 2 ready APJR agonist - GIPR Program: Developing a GIPR selective agonist and antagonist for combination therapies to treat obesity[8](index=8&type=chunk) - GCGR Program: Developing a GCGR selective agonist for combination therapies with GLP-1R[8](index=8&type=chunk) - APJR Program (ANPA-0073): A Phase 2 ready biased APJR agonist being evaluated for muscle-sparing weight loss, with long-term toxicology studies expected to be completed in 2025[8](index=8&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) The company significantly strengthened its financial position in 2024 with a substantial cash balance, despite increased operating expenses and a wider net loss [Fourth Quarter and Full Year 2024 Financial Highlights](index=2&type=section&id=Fourth%20Quarter%20and%20Full%20Year%202024%20Financial%20Highlights) The company ended 2024 with a strong **$883.5 million** cash position, extending its runway through 2027, despite increased R&D and G&A expenses and a wider net loss - Ended 2024 with **$883.5 million** in cash, cash equivalents, and short-term investments, providing a cash runway through at least 2027 for operations and key clinical milestones (excluding Phase 3 studies)[1](index=1&type=chunk)[6](index=6&type=chunk) Operating Expenses and Net Loss | Expense/Loss (in millions) | Full Year 2024 | Full Year 2023 | Change | | :--- | :--- | :--- | :--- | | R&D Expenses | $108.8 | $70.1 | +55.2% | | G&A Expenses | $49.4 | $32.7 | +51.1% | | Net Loss | $122.5 | $89.6 | +36.7% | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Operating expenses significantly increased in 2024, with R&D up 55% and G&A up 51%, resulting in a net loss of **$122.5 million** for the year Condensed Consolidated Statements of Operations (in thousands) | Metric (in thousands) | Q4 2024 | Q4 2023 | FY 2024 | FY 2023 | | :--- | :--- | :--- | :--- | :--- | | **Research and development** | $33,487 | $20,042 | $108,814 | $70,103 | | **General and administrative** | $13,574 | $10,952 | $49,414 | $32,672 | | **Total operating expenses** | $47,061 | $30,994 | $158,228 | $102,775 | | **Loss from operations** | $(47,061) | $(30,994) | $(158,228) | $(102,775) | | **Interest and other income, net** | $10,718 | $6,179 | $36,012 | $13,391 | | **Net loss** | $(36,479) | $(24,503) | $(122,526) | $(89,620) | [Condensed Consolidated Balance Sheet Data](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheet%20Data) The balance sheet strengthened significantly by December 31, 2024, with cash and equivalents increasing to **$883.5 million**, nearly doubling total assets to **$903.3 million** Condensed Consolidated Balance Sheet Data (in thousands) | Metric (in thousands) | Dec 31, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Cash, cash equivalents and short-term investments** | $883,518 | $467,323 | | **Total assets** | $903,330 | $482,017 | | **Total liabilities** | $38,487 | $29,051 | | **Total shareholders' equity** | $864,843 | $452,966 |

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a ...

Core Insights - The obesity drug sector has faced a downturn, with Structure Therapeutics experiencing an 11% decline in share price due to a competitive advertisement from Hims & Hers Health [1][2][3] Group 1: Market Dynamics - Hims & Hers Health launched a multimillion-dollar advertisement during the Super Bowl, highlighting the urgency of obesity as a health crisis and promoting its compounded semaglutide weight loss treatment [2][3] - The advertisement has raised concerns among investors regarding the competitive landscape for obesity drug developers, particularly affecting established companies like Novo Nordisk and Eli Lilly, as well as clinical-stage firms like Structure Therapeutics [3][5] Group 2: Company Performance - Structure Therapeutics is developing its investigational GS-1290 obesity treatment, which has shown promising results in a phase 2a clinical trial, outperforming Novo Nordisk's leading product, Wegovy [4][5] - Despite the competitive pressures from larger companies and high-profile marketing campaigns, there remains significant potential in the obesity treatment market, although many early-stage developers have yet to successfully commercialize their products [5]

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https: ...

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical ...

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK. Jefferies London Healthcare Conference  Format:Presentation and fi ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 23:Structure Therapeutics Inc. (GPCR) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.Structure Therapeutics' shares gained 8.7% over the last three months compared with the S&P 500’s advanced of 7.7%. The company possesses a Momentum Score of B.Rush Enterprises, Inc. (RUSHA) : This ...

Structure Therapeutics Inc. Sponsored ADR (GPCR) closed the last trading session at $40.50, gaining 17.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $87.40 indicates an 115.8% upside potential. The mean estimate comprises 10 short-term price targets with a standard deviation of $15.90. While the lowest estimate of $65 indicates a 60.5% increase from the current price level, th ...